DiscoverCME in Minutes: Education in DermatologyJonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP
Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP

Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP

Update: 2024-01-26
Share

Description

Please visit answersincme.com/PJR860 to participate, download slides and supporting materials, complete the post test, and obtain credit. In this activity, Jonathan Barker, BSc, MB, BS, MD, FRCP, an expert in dermatology, discusses unmet therapeutic needs in the treatment of generalized pustular psoriasis (GPP). Upon completion of this activity, participants should be better able to: Recognize the burden of generalized pustular psoriasis (GPP), including unmet therapeutic needs; Explain the rationale for the use of IL-36 receptor inhibitors in treating GPP; and Describe the clinical profiles of novel approved and emerging IL-36 receptor inhibitors for the treatment of GPP.
Comments 
loading
In Channel
loading
00:00
00:00
1.0x

0.5x

0.8x

1.0x

1.25x

1.5x

2.0x

3.0x

Sleep Timer

Off

End of Episode

5 Minutes

10 Minutes

15 Minutes

30 Minutes

45 Minutes

60 Minutes

120 Minutes

Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP

Jonathan Barker, BSc, MB, BS, MD, FRCP - Novel Approved and Emerging IL-36 Receptor Inhibitors for the Treatment of GPP

Answers in CME